Classification of High- and Low-Risk Patients With Dermal Leiomyosarcoma: An Exploratory Nationwide Cohort Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Risk Stratification of Patients with Dermal Leiomyosarcoma: Insights from a Nationwide Cohort Analysis

  • By

  • Kiya Abebe

  • Anders Munch

  • Anne Lene Wagenblast

  • Grethe Schmidt

  • David Hebbelstrup Jensen

  • Michael M. Petersen

  • Anand C. Loya

  • Søren Daugaard

  • Thomas Mentzel

  • Mikkel Herly

  • Peter Vester-Glowinski

  • Mathias Ørholt

  • June 15, 2026

Share

  • 1

    Dermal leiomyosarcoma (dLMS) is classified as an intermediate-risk neoplasm with a notable risk of local recurrence but low metastasis risk.

  • 2

    The study aims to identify risk factors for metastasis and local recurrence in dLMS using comprehensive data from Danish National Health Registers.

  • 3

    Atypical intradermal smooth muscle neoplasms (AISMN) may represent a low-risk subgroup of dLMS, but no significant difference in metastasis risk was found.

  • 4

    The study included all patients diagnosed with dLMS in Denmark from 1980 to 2022, ensuring accurate tumor classification through manual review.

  • 5

    Local recurrence and metastasis were defined based on specific diagnostic codes, with a focus on verifying diagnostic accuracy through pathology reports.

Original Source(s)

Classification of High- and Low-Risk Patients With Dermal Leiomyosarcoma: An Exploratory Nationwide Cohort Study

  • by Kiya Abebe, Anders Munch, Anne Lene Wagenblast, Grethe Schmidt, David Hebbelstrup Jensen, Michael M. Petersen, Anand C. Loya, Søren Daugaard, Thomas Mentzel, Mikkel Herly, Peter Vester-Glowinski, Mathias Ørholt

  • June 15, 2026

Related Content

Rapid metastatic progression of primary pulmonary synovial sarcoma despite guideline-concordant multimodal therapy: a case report

Efficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella meta-analysis

Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade